Phizzle

Phizzle provides innovative data management solutions for the pharmaceutical manufacturing sector, enhancing production efficiency and compliance through its advanced EDGMaker platform, uniquely designed to handle various scientific instruments. Founded in 2005 in San Francisco, US, Phizzle specializes in pharmaceutical data solutions. The company was co-founded by Ben Davis and Ira Shapiro. Its latest funding was a Series B round in May 2015, raising USD 4.

90 mn from Alsop Louie Partners, totaling USD 4. 90 mn in funding across four deals. Phizzle specializes in providing cutting-edge solutions for the pharmaceutical manufacturing sector, with its flagship product, the EDGMaker platform, serving as a central hub for managing drug production data. The EDGMaker is uniquely designed to facilitate data normalization and automate instrument operations, enhancing data accessibility and operational efficiency.

This software-defined architecture (SDA) enables users to manage a diverse range of scientific instruments from various vendors through a single user interface, addressing a critical need for interoperability in pharmaceutical labs. Phizzle’s client base includes pharmaceutical companies that utilize their technology for production processes, ensuring compliance with Good Manufacturing Practices (GMP) while streamlining data collection and record-keeping. Their products are primarily sold in North America and Europe, catering to both small and large molecule applications in drug manufacturing. Phizzle's revenue structure is primarily based on subscriptions and partnerships with pharmaceutical manufacturers who require advanced data management solutions for their scientific instruments.

The company offers various pricing plans which include access to the EDGMaker platform and associated services that enhance productivity and data integrity. Transactions typically occur through direct sales to B2B clients, allowing pharmaceutical companies to integrate Phizzle's technology into their existing operations seamlessly. Clients benefit from the software’s capabilities to automate processes and ensure compliance, resulting in a cost-effective solution that can significantly improve manufacturing efficiency. As Phizzle continues to expand its market presence, the financial viability of its revenue model is supported by the growing demand for advanced data solutions in the pharmaceutical industry.

Phizzle is strategically focusing on developing new features for the EDGMaker platform, with plans for a product update expected later in 2023. The company aims to expand its market presence in Asia and Latin America by 2024, seeking partnerships with local pharmaceutical firms. The recent Series B funding of USD 4. 90 mn will be utilized to support these initiatives, enhancing product development and facilitating entry into new markets.